Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 06/12/2017
Entire Document
 


Slide 21

SER-287 Phase 1b study in ulcerative colitis patients is fully enrolled Primary Objective Change in composition of intestinal microbiome at 8 weeks Safety and tolerability Secondary Objectives Clinical responses, including complete remission, and endoscopic improvement Change in serum and fecal biomarkers Complement of microbiome metabolic pathways from stool, urine and blood Immunological and pathologic changes in mucosal biopsies Arm A (n~15): Placebo pre-treatment / SER-287 once weekly dosing for 8 weeks Arm B (n~10): Placebo pre-treatment / Placebo once daily for 8 weeks Arm C (n~15): Vancomycin pre-treatment / SER-287 once daily dosing for 8 weeks Arm D (n~15): Vancomycin pre-treatment / SER-287 once weekly dosing for 8 weeks ~55 mild-moderate UC patients failing standard-of-care


© Seres Therapeutics. All Rights Reserved.